PRESSEMITTEILUNGEN

Thousand Oaks, California (ots/PRNewswire) – Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia(R) (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

Adherence to treatment, which includes both compliance (a measure of how well patients follow directions for taking medication) and persistence (a measure of whether patients continue with treatment), was measured over two years.

Results from the DAPS (Denosumab Adherence Preference and Satisfaction) study presented at the annual European Congress on Osteoporosis and Osteoarthritis (ECCEO11-IOF) in Valencia, Spain, also found that more than 90 percent of patients preferred Prolia as a treatment option over alendronate. In addition, significantly more patients were satisfied with denosumab injection compared with alendronate tablet (mean score of 4.5 vs. 3.2; score scale of 1-5, higher score, higher satisfaction, p

Trackback URL

Adherence, Alendronate, Amgen, Bisphosphonate, Daps, Denosumab, European Congress, Iof, Osteoarthritis, Osteoporosis Treatment, Ots, Persistence, Postmenopausal Osteoporosis, Postmenopausal Women, Prnewswire, Satisfaction Study, Score Scale, Thousand Oaks California, Treatment Option, Valencia Spain